The invention discloses a method for amplifying antigen-specific regulatory T cells in vitro, belonging to the technical field of biomedicine. The invention adopts Rapamycin combined with TGF-β cells to induce human T cells into antigen-specific regulatory T cells with immunosuppressive function in vitro by the action of DC cells, which has the advantages as follows: 1) the amount is sufficient; 2) the obtained regulatory T cells can resist differentiation to Th17 cells; 3) the obtained regulatory T cells have stronger inhibitory functions and biological effects compared with the regulatory T cells induced by other methods. The invention overcomes many defects of natural regulatory T cells and has greater therapeutic advantages in the treatment of inflammatory diseases, autoimmune diseases and prevention of organ transplant immunological rejection.

The present disclosure relates, at least in part, to a closed and semi-automated system for the isolation of naive T cells, their expansion, and/or final harvest. The disclosure also relates to using those isolated cells in a large batch format for compiling stocks of stimulated CD45A+ T cells and/or using the stimulated CD45A+ T cells for therapeutic purposes.

The present invention relates to a yeast-derived polysaccharide inducing Treg cells and a use thereof and, more particularly, to a polysaccharide comprising mannan and β-glucan, an composition for immunomodulation comprising the polysaccharide as an active ingredient, a pharmaceutical composition or food comprising the polysaccharide as an active ingredient for prevention or treatment of immune disease or inflammatory disease, a method for preparation of regulatory T cells by using the polysaccharide, a cell therapeutic agent comprising the regulatory T cells prepared by the preparation method as an active ingredient, and a treatment method using same. Even at a low dose, the novel polysaccharide according to the present invention allows the production of tolerogenic antigen presenting cells through the β-glucan and mannan structure retained therein, whereby the novel polysaccharide can induce the differentiation or production of antigen-specific regulatory T cells (Treg cells) to modulate the target immune system with low adverse effects. Therefore, MGCP and the Treg cells induced by the polysaccharide are effective for preventing or treating immune disease or inflammatory disease.

Provided herein are methods and systems for bio-printing of three-dimensional organs and organoids. Also provided herein are bio-printed three-dimensional organs and organoids for use in the generation and/or the assessment of immunological products and/or immune responses. Also provided herein are methods and system for bio-printing three-dimensional matrices.

The present invention relates to a method for ex vivo generating and expanding MHCII restricted CD4.sup.+ Foxp3.sup.+ regulatory T cells, and therapeutic uses thereof. The inventors here demonstrated the optimal conditions for inducing Foxp3 expression in naive CD3+ CD4+ TCRαβ+ MHCII restricted T following polyclonal or following antigen-specific activation. They also developed an experimental procedure to generate autologous CD8+ T cell lines functionally committed to lyse tumor-antigen specific FOXP3 expressing TCRαβ+ MHCII restricted T cells, pathogenic CD4+ T cells that favour tumor cell immune evasion. In particular, the present invention relates to a method for generating ex vivo MHCII restricted CD4+ Foxp3+ regulatory T cells having the following phenotype: CD3+ CD4+ Foxp3+.

This disclosure is directed to methods of preparing dendritic cells or other CD40 bearing antigen-presenting cells and methods of treating cancer by using the dendritic cells or other antigen-presenting cells in combination with anti-chemorepellant agents. This disclosure is further directed to methods of preparing T cells and methods of treating cancer, by activated T cells optionally in combination with anti-chemorepellant agents. The antigen presenting cells of the disclosure are activated by incubation with cancer cells and fusion proteins. The T cells of the disclosures are activated by incubation with activated antigen-presenting cells that were activated by incubation with cancer cells and a fusion protein. In particular, the fusion protein comprises an antigen-binding domain, e.g., an antibody or antibody fragment, and a stress protein domain.

Provided are genetically engineered induced pluripotent stem cells (iPSCs) and derivative cells thereof expressing a chimeric antigen receptor (CAR) and methods of using the same. Also provided are compositions, polypeptides, vectors, and methods of manufacturing.

Provided is a method for preparation of a composition comprising activated human CD8.sup.+ and natural killer (NK) lymphocytes. The method entails use of mature dendritic cells as feeder cells added at an early stage in CD4.sup.+ mediated activation of the CD8.sup.+ cells. Also provided is a method for treatment of cancer using the cells obtained from the process.

The generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.

Provided herein are methods for ex vivo expansion of a T cells including tumor-reactive T cells, and compositions containing such T cells. Also provided are methods for treating diseases and conditions such as cancer using compositions of the present disclosure.